Background: Following national and regional recommendations, intravenous lipid emulsion (ILE) has become established in clinical practice as a treatment for acute local anesthetic (LA) toxicity, although evidence of efficacy is limited to animal studies and human case reports. A collaborative lipid emulsion workgroup was therefore established by the American Academy of Clinical Toxicology to review the evidence on the effect of ILE for LA toxicity. Methods: We performed a systematic review of the literature published through 15 December 2014. Relevant articles were determined based on pre-defined inclusion and exclusion criteria. Pre-treatment experiments, pharmacokinetic studies not involving toxicity and studies that did not address antidotal use of ILE were excluded. Results: We included 113 studies and reports. Of these, 76 were human and 38 animal studies. One publication included both a human case report and an animal study. Human studies included one randomized controlled crossover trial involving 16 healthy volunteers. The subclinical LA toxicity design did not show a difference in the effects of ILE versus saline. There was one case series and 73 case reports of ILE use in the context of toxicity (83 patients) including CNS depression or agitation (n ¼ 45, 54%), seizures (n ¼ 49, 59%), hypotension, hypertension, EKG changes, arrhythmias (n ¼ 39, 47%), cardiac arrest (n ¼ 18, 22%), cardiopulmonary resuscitation, and/or requirement for endotracheal intubation and/or mechanical ventilation (n ¼ 35, 42%). There were 81 (98%) survivors including 63 (76%) with no reported sequelae from the LA poisoning or ILE, although the presence or absence of sequelae was not reported in 15 (18%) cases. Animal studies included 29 randomized controlled studies, three observational studies, five case series, and one case report; bupivacaine was used in 29 of these reports (76%). Of 14 controlled experiments in animals, eight showed improved survival or time to return of spontaneous circulation and five no benefit of ILE versus saline or non-ILE treatments. Combining ILE with epinephrine improved survival in five of the six controlled animal experiments that studied this intervention. The studies were heterogeneous in the formulations and doses of ILE used as well as the doses of LA. The body of the literature identified by this systematic review yielded only a very low quality of evidence. Conclusion: ILE appears to be effective for reversal of cardiovascular or neurological features in some cases of LA toxicity, but there is currently no convincing evidence showing that ILE is more effective than vasopressors or to indicate which treatment should be instituted as first line therapy in severe LA toxicity.
Introduction
There has been increasing interest in the use of intravenous lipid emulsion (ILE) for the treatment of acute local anesthetic (LA) poisoning following the publication of a case report in 2006. [1] Since then, national and regional anesthesiology societies have published recommendations for use of ILE in the treatment of LA toxicity after iatrogenic overdose. [2] [3] [4] However, evidence supporting the use of ILE in the context of toxicity involving local anesthetics or other toxins reported by previous reviews consists primarily of human case reports and controlled animal experiments that cannot necessarily be extrapolated to human clinical settings. [5] [6] [7] [8] The American Academy of Clinical Toxicology (AACT) initiated a collaboration between the European Association of Poison Centres and Clinical Toxicologists (EAPCCT), the Asia Pacific Association of Medical Toxicology (APAMT), the Canadian Association of Poison Control Centres (CAPCC), the American College of Medical Toxicology (ACMT) and the American Association of Poison Control Centers (AAPCC) to create the Lipid Emulsion Therapy in Clinical Toxicology Workgroup, which included clinical experts in clinical toxicology, anesthesiology, emergency medicine, critical care, and pharmacy with assistance of medical librarians and epidemiologists. This workgroup was tasked to review all appropriate evidence pertaining to the use of lipid emulsion in toxicology, with the ultimate goal of providing a comprehensive evaluation of the published evidence and consensus-based recommendations. [9] Here, we present the results of our systematic review of human and animal studies regarding the effect of ILE in the treatment of LA toxicity. Use for treating toxicity from other substances and adverse effects of ILE will be presented in other systematic reviews.
Methods
A working subgroup (the authors) of the lipid emulsion therapy workgroup [9] was formed to gather and review the evidence on the effect of ILE in the treatment of LA toxicity. This subgroup was formed based on the best possible match to represent the clinical experts and various stakeholders and involved in the workgroup. It also included two medical librarians who assisted in conducting the systematic searches and the retrieval of potentially eligible publications, as well as an epidemiologist with specific methodological expertise in conducting systematic reviews. Subgroup members divulged all potential conflicts of interests prior to inclusion in the workgroup. All communication was performed by email exchanges and by telephone conferences.
Two medical librarians created a systematic search strategy for Medline (Ovid), which is provided in the Appendix. The strategy comprised a combination of Medical Subject Headings, title/abstract key words, truncations, and Boolean operators, and included the concepts of ILE and toxicology (including but not limited to local anesthetics). It was subsequently translated for Embase (via Ovid), CINAHL (via EBSCO), BIOSIS Previews (via Ovid), Web of Science, Scopus, and the Cochrane Library/DARE. All databases were searched from inception to 15 December 2014. Subsequently, articles were triaged into local anesthetics and non-local anesthetics for review by each designated groups.
In addition, conference abstracts from the European Association for Poison Centers and Clinical Toxicologists, and the North American Congress of Clinical Toxicology (both from 2000 to 2014) and previous reviews were hand-searched by various group members. Abstracts from the Asia Pacific Association of Medical Toxicology were searched in the same way from 2007 to 2014. Group members also performed crossreferencing of full-text articles. No limits were applied for language, and candidate studies in languages not known to any of the authors were translated.
In summary, the criteria for publication inclusion in the evaluation of the effect of ILE include studies in humans and animals to whom ILE was given for the purpose of treating poisoning, and exclusion criteria are non-original data, animal studies with methods and results that cannot be extrapolated or are uninterpretable to humans, pre-treatment models, and experimental in vitro or ex vivo models. A complete methodology of the larger project of which this systematic review is one part was previously published, and describes in detail all relevant methodological aspects such as clinical questions, search strategies, eligibility of publications, data extraction and summary, and assessment of the risk of bias. [9] The log D, which is based on the partition coefficient, and is a measure of lipophilicity, is reported for each local anesthetic. The degree of lipophilicity directly corresponds with the log D; as the log D increases, so does the lipophilicity of a substance.
Results
Our combined search for the effect of ILE retrieved 838 full text articles that were subsequently analyzed for their pertinence to LA. Of these, 113 publications were included in our systematic review. Among the included publications, 76 were conducted in a human setting and 38 in an animal setting. One article included both a case report and an animal experiment. One human study was published as two publications. The flow diagram of study selection is presented in Figure 1 .
Human studies

Randomized controlled trials
One phase-II randomized controlled trial (unpublished, available as conference abstract at the time of writing) evaluated the efficacy of ILE on the pharmacokinetic properties of LA in 16 healthy volunteers (8 female and 8 male) aged 18-40 years (Table 1) . [10, 11] This was a double-blind crossover study consisting of a first phase of habituation to LA with an infusion of lidocaine, followed by a second phase of either a continuous infusion of ropivacaine or levobupivacaine at 8 mg/min treated with either a bolus of 120 mL of 20% ILE or of 0.9% saline, administered 2 min after the start of the LA infusion. The primary outcome of interest was the duration of drug infusion (expressed as total dose) required to induce early clinical signs of neurotoxicity such as paresthesiae and a sensation of inebriation, as evaluated by an examiner blinded to the treatment. Secondary outcome measures were detection of sub-clinical seizure activity based on electroencephalogram (EEG), duration of PR, QRS intervals based on electrocardiogram (EKG), and pharmacokinetics of local anesthetics [maximum concentration (C max ) and area under the plasma concentration versus time curve (AUC)].
No significant difference in the total LA dose given to reach early signs of clinical toxicity was observed between ILE and control groups: Ropivacaine/ILE (75.7 mg ± 29.1 mg) or saline (81.7 mg ± 22.3 mg) and Levobupivacaine/ILE (69.4 mg ± 26.2 mg) or saline (80.8 mg ± 31.7 mg; p ¼ 0.61). The LA dose was provided at 8 mg/min, and maximum allowed dose was 120 mg. Four of the 16 volunteers received the maximum dose of LA allowed in the protocol. No EEG abnormalities were seen. QRS prolongation was present at the end of the LA infusion as compared to baseline (p50.001), but no significant difference was observed between the ILE and control groups (p¼ 0.68). [11] Small pharmacokinetic differences between groups, including a 25-30% reduction in C max and a 20% increase in volume of distribution of the LA at a comparable mean dose, were not statistically significant and disappeared after 45 min [10] . The authors concluded that their study confirmed the lipid sink hypothesis in humans, but that no clinical efficacy of ILE could be observed in this systemic toxicity model, where a 3.8 ms prolongation in QRS was induced by the LA perfusion. No obvious risk of bias was identified from the research protocol (https://clinicaltrials.gov/ct2/show/NCT01602250?term¼toxalip &rank¼1), but concerns remain regarding indirectness (use of surrogate markers and uncertain generalizability to a poisoning context) and imprecision of the reported results due to the small sample size (potentially underpowered study).
No published peer-reviewed clinical controlled or observational studies were retrieved by our search. Tables 1 and 2 .
The most common lipid concentration administered in these publications was 20% (71 cases; 86%), while a 10% concentration was used in one case, [35] and the lipid concentration used was not reported in the remaining 11 cases (Table 1) . [17, 19, 23, 28, 40, 47, 51, 71] Lipid emulsion was administered as a bolus in 30 (36%) cases, as a bolus followed by infusion in 34 (41%) cases, and as an infusion without bolus in eight cases (10%). The dose regimen used was not specified or not reported in 11 (13%) cases. The median bolus dose was 0.30 g/kg (range: 0.0015-0.83 g/kg) and the median infusion dose was 1.9 g/kg/h (range: 0.015-6.0 g/kg/h). Overall, the total volume of lipid emulsion administered ranged from 9 to 2480 mL ( Table 1 ). The bolus dose in infants up to the age of 1 year was 1-2 mL/kg (Table 1) .
In 52 cases (63%), the lipid emulsion used was IntralipidÔ; other formulations used were MedialipidÔ (n ¼ 3, 4%), LipofundinÔ (n ¼ 3, 4%), LiposynÔ (n ¼ 2, 2%), LipovenoesÔ (n ¼ 1, 1%), KabivenÔ (n ¼1, 1%), and IntraliposÔ (n ¼ 1, 1%). In 20 cases (24%), the lipid emulsion formulation was not reported (Table 1) .
Sixty-nine (83%) patients experienced toxicity following the use of local anesthetics for nerve blocks (Table 1 ), including 10 cases described in the single case series (Table 1) . [19] Toxicity was also reported after intravenous (n ¼ 4; 5%), [25, 32, 51, 74] subcutaneous (n ¼ 6; 7%), [12, 19, 29, 33, 44, 54] intraosseous (n ¼ 1; 1%), [31] topical (n ¼ 1; 1%), [45] intraperitoneal (n ¼ 2; 2%), [44, 65] intraarticular (n ¼ 1; 1%), [29] and intrapleural administration (n ¼ 1; 1%). [39] Two routes of administration were involved in three cases (4%) [29, 44, 65] and the route was not reported in one case (1%) ( Table 1) . [40] The most frequent toxic effects from LA reported were central nervous system (CNS) features including (but not limited to) CNS depression/coma or agitation (n ¼ 45; 54%) and seizures (n ¼ 49; 59%). Cardiovascular features included hypotension, hypertension, EKG changes and arrhythmias (n ¼ 39; 47%), and cardiac arrest (n ¼ 18; 22%); other non-cardiovascular symptoms (n ¼ 22; 27%) were also common (Table 1) .
In 14 cases (17%), [21, 35, 37, 42, 44, 46, 48, 51, 52, 61, 63, 65, 74, 80 ] ILE was the only treatment used for reversal of toxic effects and in 10 (12%) of these resolution of symptoms was reported. [21, 35, 42, 44, 46, 48, 52, 61, 65, 74] In four (5%) cases, the authors reported that it was unclear if effects were related to ILE. [37, 51, 63, 80] One case report did not comment on ILE effects [46] (Table 1) .
Sixty case reports (72%) described the use of ILE in combination with additional treatments. In 35 (42%) cases, lipid emulsion was used after failure of other treatments, in six (7%) cases before other treatment, and in 16 (19%) cases lipid emulsion was used concomitantly. The sequence of treatment was not reported in three (4%) cases (Table 1) . Other treatments used included benzodiazepines or other sedatives (n ¼ 41; 49%), vasopressors (n ¼ 29; 35%), sodium bicarbonate (n ¼ 7; 8%), anti-arrhythmic drugs (n ¼ 9; 11%), intravenous fluids (n ¼ 5; 6%), and/or other treatments (n ¼ 20; 24%). Three studies (4%) reported other but unspecified treatments. Cardiopulmonary resuscitation (CPR) and/or intubation and/or ventilation were initiated in 35 (42%) cases. In three (4%) cases, the patient was already intubated when features of LA toxicity appeared. Oxygen supply by mask was initiated in nine cases (11%). Cardiac defibrillation was reported in four cases (5%). CPR and/or intubation were not required in 19 (23%) cases and use of these procedures was not reported in 16 studies (19%; Table 1 ). Nine case reports did not state if any other treatments were performed ( Table 1) .
The authors of these case reports observed that ILE had a possible beneficial effect or was the cause of resolution of toxic features in 59 of cases (71%). Four case reports (5%) suggested no benefit from ILE. In 10 case reports (12%), it was unclear whether benefits were related to ILE or not; the effect of ILE was not described in 10 other cases (12%; Table 1 ).
Animal studies
Among the 38 publications using animal models, 29 (76%) were randomized controlled studies (11 studies on rats, 14 on pigs, 2 on dogs, and 2 on rabbits) [17, , three (8%) were observational studies (1 study on pigs, 1 on rats, and 1 on rabbits) [113] [114] [115] , five (13%) were case series (1 study on rabbits and 4 on rats), [116] [117] [118] [119] [120] and one (3%) was a case report (cat). [121] The animal studies are summarized in Table 3 .
The local anesthetics used the 38 publications included bupivacaine (n ¼ 29 studies, 76%) levobupivacaine (n ¼ 5, 13%), lidocaine (n ¼ 1, 3%), mepivacaine (n ¼ 1, 3%), and ropivacaine (n ¼ 4, 11%). Two studies combined two local anesthetics, bupivacaine/mepivacaine and levobupivacaine/ropivacaine (Table 3) .
Lipid concentrations used were 20% (n ¼ 22, 58%), 30% (n ¼ 8, 21%), or not described (n ¼ 2, 5%). A bolus dose was used in 29 (76%) studies and was followed by an infusion in 22 studies (58%). In three (8%) studies, an infusion was used without an initial bolus. The median bolus dose was 0.80 g/kg or 4 mL/kg of 20% ILE (range: 0.20-3.0 g/kg) and median infusion dose was 6.0 g/kg/h (range: 0.60-54 g/kg/h). In 22 studies (58%), the lipid emulsion used was IntralipidÔ while two studies used the medium chain/long chain triglyceride preparations LipovenosÔ MCT (n ¼ 2, 5%) or MedialipidÔ (n ¼ 1, 3%). Other products used in one study each (3%) were LipovenosÔ, IvelipÔ, SMOFLipidÔ, ClinOleicÔ, and Liposyn IIÔ; an un-named Soybean oil emulsion was used in one study and the ILE formulation used was not reported in five studies (Table 3) .
Animal randomized controlled studies
In 12 of the 29 randomized controlled studies, ILE was compared to the vasopressors epinephrine and/or vasopressin, either alone or in combination, or with vasopressors combined with ILE (Table 3) . [88, 89, 91, 92, 97, [102] [103] [104] [105] 107, 110, 111] The ILE versus epinephrine studies [88, 89, 91, [102] [103] [104] 107, 110, 111] showed therapeutic benefit on survival or return to spontaneous circulation for ILE compared to epinephrine in four studies (14% of the animal RCS) [102] [103] [104] 107] and for epinephrine + vasopressin in one study (3% of the animal RCS). [105] There were comparable efficacy of ILE and epinephrine in five studies (17% of the animal RCS). [88, 89, 91, 110, 111] Combining epinephrine + ILE gave a better survival outcome compared to ILE alone in six studies (21% of the animal RCS), [88, 89, 97, 102, 104, 111] and of these, two studies concluded comparable efficacy of epinephrine and epinephrine + ILE. [102, 104] In two studies (7% of the animal RCS), the combination vasopressin + ILE did not improve survival over ILE alone and was not as effective as epinephrine or epinephrine + ILE treatment. [102, 104] ILE was superior in one study (4% of the animal RCS) comparing ILE with vasopressin alone or epinephrine + vasopressin. [92] Lipid infusion was compared to crystalloids, either saline [17, [85] [86] [87] 90, 91, 94, 96, 97, [106] [107] [108] [109] [110] [111] or Ringer's acetate [101] in 15 of the 29 randomized controlled studies (Table 3) . Nine (31% of the animal RCS) studies showed therapeutic benefit [85, 87, 90, 91, 94, 97, 106, 109, 110] and six (21%) no benefit if ILE. [17, 86, 96, 101, 107, 111] In one study comparing ILE and saline, the control groups were different (electrically initiated ventricular fibrillation versus LA induced venticular fibrillation); this study was therefore considered not useful for evaluating the efficacy of ILE. [108] Various LA doses were evaluated in the included studies, and these doses were provided in varying units. These doses depended on the type of LA and the secondary outcome symptom severity. For bupivacaine, used in 22 (76%) out of the 29 studies, [86, 87, [90] [91] [92] [93] [94] [95] [96] [97] [100] [101] [102] [103] [104] [105] [106] [108] [109] [110] [111] [112] ] the dose ranged from 1 mg/kg/min to 10 mg/kg/min given over 10 s or 4-30 mg/kg (Table 3) . Levobupivacaine was used in four studies (14%), [88, 89, 98, 99] with a dose of 500 mg/h, [88] 10 mg/kg, [99] or 3-8.3 mg/kg/min. [89, 98] Mepivacaine was used in one study (3%) at an infusion rate of 6 mg/kg/min. [101] Ropivacaine was used in three studies (10%), [17, 85, 107 ] at 1.5 mg/kg/min as lowest infusion dose up to a maximum of 14.9 ± 2.8 mg/kg given as a bolus (Table 3) . Resuscitation treatments were generally initiated immediately or within 3 min of the termination of LA administration (Table 3) . Intravenous lipid emulsion was initiated immediately or within one minute in 19 studies [17, 85, 87, 90, 92, 94, 96, 98, [100] [101] [102] [103] [104] 106, 110, [116] [117] [118] [119] or less commonly up to 3 min (two studies), [97, 105] 4 min (one study), [86] 10 min (two studies), [109, 111] or 20 min (one study) [108] after termination of LA administration. The timings of administration of study treatments were not reported in three studies (10%). [88, 91, 107] Three studies (10%) were not designed to evaluate the therapeutic effects of ILE alone, and either compared the use of ILE for toxicity caused by two different local anesthetics, [101] compared two types of ILE (long-chain triglyceride versus long-chain and medium-chain triglyceride [100] ) or evaluated the myocardial tissue pH. [108] These studies were not considered generalizable to human poisoning and were therefore excluded from further analysis.
Animal observational studies
The three observational studies included in this review measured the LA dose required to cause death in 50% of the animals dosed (LD50), [115] compared the effect of ILE or saline on QRS widening using ILE or saline, [113] or compared ILE to hypertonic saline in combination with ILE. [114] Intravenous lipid emulsion was initiated immediately or within 2 min of the termination of LA administration (Table  3) . Bupivacaine was used at 4 mg/kg, [113] 10 mg/kg, [114] or at several different doses. [115] A benefit of ILE use was supported by the demonstration that lipid infusion increased the bupivacaine LD50 in rats by 48%, from 12.5 to 18.5 mg/kg, [115] and by reversing the lengthening of QRS interval induced by the injection of bupivacaine in pigs (Table 3) . [113] Animal case reports and case series Only one animal case report was retrieved from our literature search, describing a cat suffering from toxicity after administration of lidocaine 140 mg (20 mg/kg). [121] The ILE infusion regimen was derived from clinical human studies, but the dose was reduced due to concerns about fluid overload. The authors reported a pronounced clinical response within 15 min of ILE initiation, with the cat becoming more responsive to stimuli and being able to hold its head up without assistance.
Five studies were included in this review as case series as the studies did not include a control group without ILE or included ILE in both study groups. [116] [117] [118] [119] [120] Thus, one study compared ILE plus the addition of three different doses of epinephrine, [116] one study compared the effect of ILE for either levobupivacaine or ropivacaine toxicity, [120] and three studies evaluated if the protective action of lipid emulsion was mediated through the fatty acid oxidation pathway [117, 118] or involved the opioid receptor. [119] Bupivacaine 10 mg/kg was the LA used in four of these five studies, [116] [117] [118] [119] and levobupivacaine and ropivacaine were used in the other study each at a dose of 2 mg/kg/h. [120] Intravenous lipid emulsion was initiated immediately or up to 1 min after LA administration.
Assessment of the quality of evidence Table 4 presents the summary estimates with associated Grading of Recommendations Assessment, Development and Evaluation (GRADE) ratings for the two human controlled studies reporting the efficacy of ILE on LA cardiotoxicity and neurotoxicity. All other evidence retrieved in this systematic review was rated as of very low quality; the human studies were seriously limited by their study designs (all uncontrolled studies preventing comparison with a control group, such as case series and case reports) and by the high likelihood of publication bias (especially with case reports), while animal studies were seriously limited by indirectness (resuscitation model lacking generalizability to humans) and imprecision (systematically underpowered studies). [122] [123] [124] [125] [126] [127] [128] 
Discussion
In our systematic review on the effect of ILE for acute LA toxicity, we identified animal and clinical studies that yielded a very low quality of evidence. Most randomized studies were conducted in animal settings with limited observation of test subjects after treatment and where no autopsies were performed or drug concentration measured. The human publications presenting the effect of ILE in severe LA toxicity were mainly case reports. Data from these studies and reports showed inconsistent benefits of ILE for the treatment of acute LA intoxication. Many also employed several treatments and, although this reflects what often happens in clinical practice, it makes the assessment of the specific effects of ILE difficult if not impossible.
A possible beneficial effect was reported in 71% of the human case reports, although this estimate of benefit is questionable due to the high risk of publication bias usually associated with this specific study design and due to the indirectness of the results caused by the absence of comparison to a control group. Furthermore, the only human controlled study showed no effect of ILE on mild LA toxicity. Thus, most of the useful evidence supporting a beneficial effect of ILE relies on animal studies. In controlled animal experiments and animal observational studies, the effects of ILE were mainly based on cardiovascular variables, which are the most frequently observed adverse events with bupivacaine, the LA most often studied. Neurological symptoms could not be fully evaluated as the animals used were anesthetized during the experimental procedures. Results suggested improved efficacy for the reversal of LA cardiovascular toxicity with ILE alone compared to other treatments received alone in 48% of the controlled animal studies, but reduced efficacy was seen in 28% of the these studies. The dose of LA given to induce toxicity in animals may not be comparable to the toxic dose known in humans and the amount of ILE given bolus often exceeded current recommendations.
When ILE was compared to other active treatments (vasopressors), inconsistent results were observed. There were 13 controlled animal studies favoring ILE alone, six studies favoring vasopressors and seven studies favoring the combination of vasopressors and ILE. These studies are too heterogeneous to allow a pooled analysis. The limited results of the available observational studies also suggested a possible clinical benefit from ILE alone or in combination with other resuscitative treatments with the same limitations to the human poisoning context as stated previously.
From the eight animal experiments using vasopressors and ILE, results appears to be conflicting and in particular with the use of epinephrine. On the one hand, ILE appears to be associated with better hemodynamic outcomes in one study. [110] On the other hand, epinephrine alone, or the association of epinephrine and ILE, was better than ILE alone for survival or hemodynamic outcomes in five other studies in pigs and rats. [102] [103] [104] 107, 111] It is worth noting that the amount of epinephrine and ILE given were quite heterogeneous and the formulation of ILE was not reported in one publication. Finally, two studies demonstrated that no differences between epinephrine and ILE for mortality. [88, 97] Thus, data from the human case reports and the animal studies provides weak evidence that that ILE may be effective in some cases of LA toxicity. However, there is no convincing evidence that this treatment is more effective than the use of vasopressors. These results also do not offer evidence to support which treatment should be instituted as first line therapy when cardiovascular toxicity arises after LA anesthetic administration.
Limitations
We performed a very broad search of the literature using appropriate eligibility criteria by considering all types of study design, including preclinical studies, but we may not have uncovered all studies reported in abstract form. A further potential limitation of our review is the inclusion of animal studies, which may not be generalizable to human cases of LA poisoning. The consideration of animal studies to support clinical practice may be perceived as inappropriate by some. However, several editorials and reviews used animal data to support the concept of ILE as an antidote. Our decision to consider such methodology was driven by our intention to be as exhaustive as possible in a field where very little research is conducted, and when it is done, this is often in a non-optimal context.
The human cases described were also heterogeneous regarding the LA involved, the severity of symptoms, the ILE dose, and the use of other treatments before ILE and we could not explore the potential impact of these discrepancies on the effect of the intervention. As stated in our methodology paper, [9] the primary outcome of interest was survival. The included case reports showed 98% survival. However, the validity of this finding is questionable due to reporting and publication bias. In most of the case reports, the reversal of toxicity was thought to be related to ILE, however, some uncertainty remains as other treatments were often provided at the same time and effects could not be specifically distinguished. Furthermore, it is likely that cases that described negative outcome after ILE administration are underreported. Quality assessment according to the GRADE methodology. Of note, since no controlled studies were pooled together to answer a specific clinical question, inconsistency and publication bias were not evaluable.
Our inability to deliver some of the results as intended in our methodology paper [9] , was principally due to unreported data, insufficient data, or the nature of the data, and also included the units used to specify the dose. Our intention was to extract or calculate the total amount of ILE in g/kg, but in many articles the information was insufficient, and therefore different units appears in Tables 1 and 3 . As mentioned in the 'Results' section, most of the included studies and reports used 20% ILE, but a limitation to this review is that in 11 human case reports and two animal studies, the actual concentration of the ILE used was not reported.
A further limitation of the data was that it was not easy to obtain information if reported sequelae in human case reports referred to adverse effects from local anesthetics or from ILE. The details of sequelae that we were able to extract from data are included in Table 1 .
Conclusions
The currently available published evidence concerning the effect of ILE in severe LA toxicity is limited to very low quality studies such as small animal experiments and human and animal case reports or series. It is possible that ILE may be effective for reversal of cardiovascular or neurological features in some cases of LA toxicity. However, there is currently no consistent evidence that ILE is more effective than vasopressors. The available evidence is insufficient to judge the combined effects of ILE and vasopressors and to determine whether one drug should precede the other in treating severe LA toxicity.
